Novo Nordisk's Multi-Front Storm: Legal Action, Mass Layoffs, and a Stock Losing Its Footing
Published on 08/18/2026 at 10:52 | Redaktion boerse-global.de
The Danish pharmaceutical heavyweight is fighting battles on several fronts at once. Novo Nordisk has filed a lawsuit against Eli Lilly, accusing its arch-rival in the weight-loss drug arena of running advertisements that falsely claim superiority for its GLP-1 treatments over Novo's own products. The legal salvo, reported by The Daily Upside, lands at a moment when competition for dominance in the lucrative obesity market has never been fiercer.
For Novo, the stakes are existential in commercial terms. Marketing messages that cast doubt on the efficacy of its injectable therapies could translate directly into lost prescriptions and eroded market share. The share price, currently hovering at €39.02, has already shed 4.8 percent over the past seven trading sessions — a reflection of how investors are pricing in the mounting pressure.
A Regulatory Blow Adds to the Gloom
Compounding the legal headache is a fresh safety concern. European prescribing information for semaglutide, the active ingredient in Novo's blockbuster obesity and diabetes drugs, has been updated to include a warning about NAION, a form of optic nerve stroke. While the company insists that an analysis of 96,000 patients found no proven causal link, the cautionary note is likely to give physicians and patients pause at a time when Novo is already working to shore up its safety reputation.
The bad news has arrived in clusters. Roughly two weeks ago, the company disclosed disappointing results from the Phase 3 ZEUS trial, where Ziltivekimab failed to hit its primary endpoint in cardiovascular disease patients. That setback triggered write-downs totalling 6.3 billion Danish kroner, including 4.0 billion tied to the pipeline candidate Monlunabant, further souring sentiment.
5,000 Job Cuts and a CEO on the Defensive
On the home front, the company is navigating its largest workforce reduction in Danish corporate history. Approximately 5,000 employees face potential redundancy, and the announcement has ignited a public row. CEO Mike Doustdar took the unusual step of addressing the controversy directly on LinkedIn on Monday, responding to criticism from unions and a former company stress ombudsman about his leadership style and the internal work culture.
Works councils are scrambling to limit the scale of the cuts, while union leaders like Sara Vergo of Djøf are at least pushing for solid re-employment prospects for affected members. Doustdar's decision to engage publicly marks a notable shift in corporate communications — whether it reads as transparency or damage control is very much in the eye of the beholder.
When workplace restructuring brings disruption, safety documentation often falls by the wayside. Yet keeping your risk assessments current is a legal duty that doesn't pause during periods of change. A free toolkit with 41 ready-to-use templates and checklists helps you stay compliant without adding to the workload. Download the free Risk Assessment Toolkit
The personnel crisis lands on a company already wrestling with competitive pressure. Danish commentators have pointed out that the domestic C25 index has managed only a 4.1 percent gain this year, trailing European and US benchmarks significantly — a lag attributed in large part to Novo's weakness, particularly after its CagriSema pipeline disappointed. Those trial results, unveiled about a fortnight ago, have since knocked 2.6 percent off the share price.
Cloud Partnership Offers a Counterweight
Not every headline has been negative. Novo has named Amazon Web Services its preferred cloud provider and strategic AI partner, with a new co-innovation hub in London designed to accelerate drug development. The move, covered by PharmaTimes, signals a longer-term bet on digital capabilities to diversify beyond the blockbuster products that currently dominate its fortunes.
Yet regulatory complications persist across the Atlantic. The FDA has designated Novo's manufacturing facility in Bloomington, Indiana, as "Official Action Indicated" following an April inspection. As a consequence, partner Scholar Rock was forced to remove the site from its regulatory application for Apitegromab, according to BioSpace.
The Market's Verdict So Far
The share price tells a sobering story. The stock closed yesterday at €38.87, trading below all key moving averages and sitting 3.5 percent beneath its 200-day line. From the 52-week high of €54.86, reached in late January, the shares have retreated roughly 29 percent. Year-to-date, the decline stands at 11 percent, extending to 16 percent on a twelve-month view.
Berenberg had already downgraded the stock from "Buy" to "Hold" earlier this month, trimming its price target in the process. Operationally, Novo has raised its full-year guidance multiple times, most recently in August, though analysts were largely unmoved by the upgrades. Weak second-quarter sales figures for its top products, coupled with an unresolved US securities lawsuit — a federal judge recently allowed parts of the claims concerning allegedly misleading statements around the CagriSema REDEFINE 1 study to proceed — continue to weigh on investor confidence.
Regulatory scrutiny isn't limited to the pharmaceutical sector. UK employers face their own compliance pressures when it comes to hazardous substances — and getting it wrong can mean substantial fines. A free COSHH toolkit with 43 customisable templates and checklists helps you meet your legal duty to assess risks from dangerous substances. Get the free COSHH Toolkit
The question now is whether the legal fight with Eli Lilly, the safety warning, and the workforce upheaval will prove manageable distractions or compounding factors that entrench the downward trajectory. For a company that once seemed untouchable in the obesity treatment boom, the road ahead looks considerably more uncertain.
